InsidersTradesSigma
NA
NanoRepro AG Stock: price and management transactions · Germany · BaFin
Follow the NanoRepro AG stock price and the full management transaction log of the company, a listed issuer based in Germany. Shares trade on DE DE, under the supervision of BaFin. Operating in the Healthcare & Pharma sector, NanoRepro AG has recorded 13 public disclosures. Market capitalisation: €27.2m. The latest transaction was disclosed on 1 June 2026 (Buy). Among the most active insiders: Stiller, Dr. Olaf. All data is accessible without an account.
13
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate NanoRepro AG Strong Buy (bullish), based on 2 analysts. Average price target: €4.40.
28Σ signal
Fundamental score
Ranked 15,469 of 26,092 companies
46.3
score / 100
Value57
Quality36
FCF yld35%
Earn yld-7.5%
EV/EBITDA·
ROE-4.5%
Gross mgn63%
Net mgn-44%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 1 June 2026
Declarations13 total
5,434.783 shares@ €1.840.057% mcap17.5% of flowShareXetraBAFIN:40009328-25747d80e189
6,983.641 shares@ €1.840.073% mcap27.3% of flowShareXETRABAFIN:40009328-a8f95c647da8
30 shares@ €1.730.0003% mcap0.1% of flowShareXETRABAFIN:40009328-039c2b31aff5
1,565.279 shares@ €1.790.016% mcap8.2% of flowShareXETRABAFIN:40009328-8cdab42a3773
10,000 shares@ €1.750.099% mcap23.1% of flowShareXETRABAFIN:40009328-8847603b3e3a
5,570.874 shares@ €1.750.055% mcap28.5% of flowShareTradegateBAFIN:40009328-bfb6e96c25db
5,965.031 shares@ €1.630.055% mcap16.7% of flowSharexetraBAFIN:40009328-42fbba4a4565
6,369.427 shares@ €1.570.057% mcap17.2% of flowShareXETRABAFIN:40009328-c61cad71e889
1,750.617 shares@ €1.620.016% mcap4.9% of flowShareXetraBAFIN:40009328-d93c9ec726dd
6,289.308 shares@ €1.590.057% mcap17.2% of flowShareTradegateBAFIN:40009328-78add94750d0
5,010.886 shares@ €1.5836.5% of flowShareTradegateBAFIN:40009328-903602c6404d
8,494.34 shares@ €1.6263.5% of flowShareTradegateBAFIN:40009328-79567ed7ab47
20,078.125 shares@ €1.2833.9% of flowShareXETRABAFIN:40009328
13 of 13 declarations
About NanoRepro AG
NanoRepro AG is a German listed company traded on Xetra/Frankfurt (DAX/MDAX/SDAX) and headquartered in Marburg, Hesse, Germany. Since its stock market listing in October 2008, the group has focused on the development, manufacturing and distribution of rapid diagnostic self-tests for home and professional use, together with food supplements. Its core positioning is in preventive healthcare and self-diagnostics, a market supported by rising health awareness, consumer demand for convenient at-home testing, and multi-channel distribution across pharmacy, retail and online channels. ([nanorepro.com](https://www.nanorepro.com/en/company?utm_source=openai)) From a business-model perspective, NanoRepro built its franchise around the “ZuhauseTEST” brand and a CE-marked portfolio covering areas such as fertility, pregnancy, gastric health, intolerances, allergies, preventive screening and infectious diseases. The company emphasizes product flexibility, just-in-time manufacturing and ongoing cost optimization, which are important advantages for a niche diagnostics player operating in a fast-moving consumer-health environment. Alongside diagnostics, NanoRepro has offered food supplements under the ALPHABIOL brand since 2015, allowing it to cross-sell within adjacent health and wellness categories. ([nanorepro.com](https://www.nanorepro.com/unternehmen?utm_source=openai)) In competitive terms, NanoRepro is best viewed as a focused small-cap specialist rather than a fully integrated large healthcare group. Its edge lies in speed, targeted product launches, and the combination of diagnostics with consumer health products. The company serves both domestic and international markets, although Germany remains the anchor market and operational base. Recent disclosures also indicate growing retail presence, including listings with major German drugstore partners, which supports broader brand visibility and distribution reach. ([nanorepro.com](https://www.nanorepro.com/en/company?utm_source=openai)) Recent developments are especially relevant for investors. After the COVID-test windfall faded, NanoRepro reported a clear recovery in its underlying business in 2024, with core revenue outside COVID rising by roughly 76% and total revenue reaching about EUR 4.4 million. Subsequent half-year and full-year updates for 2024/2025 show continued momentum in self-tests and supplements, while profitability is still in transition. At the same time, the company has broadened its strategic optionality through a majority stake in Paedi Protect AG and a 2025 investment in hyped about science GmbH, linked to cold-plasma technology and the PHLAS consumer device. For international equity investors, NanoRepro combines healthcare exposure, balance-sheet-driven caution, and a diversification strategy that is still being built out. ([nanorepro.com](https://www.nanorepro.com/presse-news/pressemitteilungen-de/nanorepro-veroeffentlicht-halbjahreszahlen-2024-umsatz-im-kerngeschaeft-steigt-investitionen-in-markenbekanntheit-zahlen-sich-aus?utm_source=openai))
